QTTB vs. ACRS, CMRX, LFVN, VACC, BRNS, YS, ONCY, SPRO, MIST, and CNTB
Should you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Aclaris Therapeutics (ACRS), Chimerix (CMRX), LifeVantage (LFVN), Vaccitech (VACC), Barinthus Biotherapeutics (BRNS), YS Biopharma (YS), Oncolytics Biotech (ONCY), Spero Therapeutics (SPRO), Milestone Pharmaceuticals (MIST), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical preparations" industry.
Aclaris Therapeutics (NASDAQ:ACRS) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
In the previous week, Aclaris Therapeutics had 17 more articles in the media than Q32 Bio. MarketBeat recorded 22 mentions for Aclaris Therapeutics and 5 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.92 beat Aclaris Therapeutics' score of -0.34 indicating that Aclaris Therapeutics is being referred to more favorably in the media.
Aclaris Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500.
98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 5.5% of Aclaris Therapeutics shares are held by insiders. Comparatively, 16.1% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aclaris Therapeutics has higher revenue and earnings than Q32 Bio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
Aclaris Therapeutics currently has a consensus price target of $22.25, suggesting a potential upside of 1,785.59%. Q32 Bio has a consensus price target of $47.50, suggesting a potential upside of 71.17%. Given Q32 Bio's higher probable upside, equities research analysts plainly believe Aclaris Therapeutics is more favorable than Q32 Bio.
Aclaris Therapeutics received 375 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 66.96% of users gave Aclaris Therapeutics an outperform vote.
Q32 Bio has a net margin of 0.00% compared to Q32 Bio's net margin of -248.28%. Q32 Bio's return on equity of -61.03% beat Aclaris Therapeutics' return on equity.
Summary
Aclaris Therapeutics beats Q32 Bio on 11 of the 18 factors compared between the two stocks.
Get Q32 Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
